Mr. Thomas Smeenk reports

HOWIE'S 17+ YEARS AFTER VESCELL: FOLLOWING HEMOSTEMIX'S HEART PATIENTS

Hemostemix Inc. has celebrated the 17-plus years of life gained by Howie Lindeman, the results of Mr. Lindeman's VesCell treatment in 2008.

Florida's law now authorizes the use of VesCell in patients with life-threatening or debilitating conditions who have exhausted standard-of-care treatment options. To explain the 17 years he gained from one VesCell treatment for ischemic cardiomyopathy, Howie Lindeman, a six-time Grammy Award-winning producer and recording engineer, shared his experience as one of VesCell's longest-living recipients.

A family history and a life-changing decision

At the age of 39, Mr. Lindeman suffered his first heart attack, marking the beginning of his battle with severe heart disease. As patient treated in 2008, Mr. Lindeman's journey offers a helpful testament to those individuals who have no-option cardiovascular disease.

Mr. Lindeman's heart condition was not unexpected, given his family history. Both his father and grandfather succumbed to coronary artery disease. Facing the prospect of open-heart surgery, Mr. Lindeman sought alternatives to the invasive procedure. His research led him to VesCell, an innovative therapy using a patient's own blood-derived stem cells to restore circulation and improve cardiac function. "I was determined to find another way," Mr. Lindeman shared in his testimonial, reflecting on his decision to pursue VesCell over traditional surgery. His choice was informed by a review of clinical data and the therapy's potential to address his ischemic cardiomyopathy as an alternative to open heart surgery.

Life before and after VesCell

Before treatment, Mr. Lindeman described his quality of life as severely diminished, a common experience for those with advanced heart disease. "I thought my life as I knew it was over," he recalled, noting the fatigue and limitations imposed by his condition. After receiving VesCell (ACP-01), Mr. Lindeman experienced a dramatic improvement. His ejection fraction, (volume of blood ejected with each heart beat) nearly doubled, from the low-20-per-cent range to the 40-per-cent range, as noted in his interview. "This therapy gave me my life back," Mr. Lindeman said. "I feel stronger, healthier and more hopeful than I ever thought possible."

Lessons learned and a message of hope

Mr. Lindeman's experience underscores the potential of stem cell therapy to improve ejection fraction and survival in heart failure patients. A 2025 peer-reviewed article in Cells (June 29, 2025) highlights how VesCell (ACP-01) fosters angiogenesis and reduces inflammation, offering a scientific foundation for its benefits.

Mr. Lindeman's story also emphasizes the importance of exploring innovative treatments when standard options fall short. "I learned to never give up hope and to seek out solutions that align with your body's natural healing potential," he shared.

Hemostemix's VesCell has treated 498 patients across seven clinical studies, with results published in 11 peer-reviewed publications. In peer-reviewed published studies, the therapy has shown up to a 47.1-per-cent increase in ejection fraction in dilated cardiomyopathy patients.

"Stories like Howie's are our drum beat. They inspire us to make VesCell widely available to patients who have no other options," said Thomas Smeenk, chief executive officer.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed and patented, and is scaling and selling, autologous (patient's own) blood-based stem cell therapy, VesCell (ACP-01). A recent peer-reviewed article in Cells (June 29, 2025) provides the scientific foundation for how ACP-01 and NCP-01 may enhance brain-computer interface performance by reducing inflammation, fostering angiogenesis and synaptic plasticity, and potentially extending implant longevity. Hemostemix has completed seven clinical studies of 318 subjects and published its results in 11 peer-reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure and angina. Hemostemix completed its phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared with a five-year mortality rate of 50 per cent in the CLTI patient population, the University of British Columbia and University of Toronto reported to the 41st meeting of vascular surgeons: 0-per-cent mortality, cessation of pain, wound healing in 83 per cent of patients followed for up to 4.5 years, as a midpoint result.

We seek Safe Harbor.